BioSpace1m
Gilead Partners With Generics Developers to Provide HIV Drug to Low-Income Countries
Gilead Sciences is granting licenses to six companies to produce lenacapavir for pre-exposure prophylaxis, as well as for ...
BioSpace51m
CMS Releases Updated Medicare Drug Price Negotiation Guidance, Offers More Flexible Timeline
The adjusted guidelines will provide drugmakers with more opportunities to engage with the Centers for Medicare and Medicaid ...
BioSpace3h
Lilly’s Tirzepatide No Longer on FDA Drug Shortage List
BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, which is growing market ...
BioSpace23h
Lilly to Invest $4.5B in New Indiana Manufacturing and R&D Center
Eli Lilly’s investment in the LEAP Research and Innovation District in Lebanon, Indiana, has now jumped to more than $13 ...
BioSpace23h
More Layoffs From ImmunityBio, Bringing California’s Fall Cuts to 31
ImmunityBio will lay off 15 employees in California, mostly in El Segundo, effective Nov. 25. The company is also letting go ...
BioSpace23h
As 2seventy Nears Breakeven, CEO Chip Baird Explains How the Team Survived
To say that 2seventy bio’s short two years of existence have been dramatic is an understatement. CEO Chip Baird told BioSpace transparency and a committed staff have kept the biotech going through ...